EMEA-002220-PIP01-17

Key facts

Active substance
  • Influenza virus H1 haemagglutinin
  • influenza virus H3 haemagglutinin /influenza virus haemagglutinin from strain B Victoria lineage
  • influenza virus haemagglutinin from strain B Yamagata lineage (expressed as virus-like particle [VLP])
Therapeutic area
Vaccines
Decision number
P/0118/2018
PIP number
EMEA-002220-PIP01-17
Pharmaceutical form(s)
Solution for injection
Condition(s) / indication(s)
Prevention of influenza
Route(s) of administration
Intramuscular use
Contact for public enquiries
Medicago Inc.
Tel.: +418 6589393 ext 156
E-mail: martrejl@medicago.com
Decision type
P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)

Decision

How useful was this page?

Add your rating